Cantor Fitzgerald Reiterates Overweight on Xenon Pharmaceuticals, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Xenon Pharmaceuticals (NASDAQ:XENE) and maintained a $65 price target.
August 09, 2024 | 3:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Xenon Pharmaceuticals and maintained a $65 price target.
The reiteration of an Overweight rating and a maintained price target of $65 by a reputable analyst is likely to positively impact investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100